toripalimab + chemotherapy (Junshi Biosciences)

This neoadjuvant treatment regimen combines **toripalimab**, a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, with platinum-based chemotherapy (typically paclitaxel plus cisplatin or gemcitabine plus cisplatin). Toripalimab functions as an immune checkpoint inhibitor, blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2) to restore T-cell mediated anti-tumor activity. The chemotherapy component provides direct cytotoxic effects, potentially increasing tumor antigen release and enhancing the immune response. This specific combination is being investigated by the Second Affiliated Hospital of Zhejiang University School of Medicine as a neoadjuvant therapy for patients with locally advanced, resectable, HPV-negative head and neck squamous cell carcinoma (HNSCC) to reduce tumor burden prior to surgical intervention.

Brand names

Tuoyi

Other names

Toripalimab with Neoadjuvant ChemotherapyToripalimab + paclitaxel + cisplatinToripalimab + gemcitabine + cisplatin